The University of Strathclyde’s Continuous Manufacturing and Crystallisation Centre (CMAC) is a world-class international hub for manufacturing research and training. Working in partnership with industry, its purpose is to transform current manufacturing processes into the medicine supply chain of the future.
The Centre uses revolutionary manufacturing techniques developed to speed up the process of bringing new drugs to market, and help make precision medicine an economically viable reality.
The centre, in collaboration with partners including Graz and Nanyang Technological University, provides CMAC with an industrial base in the local region, and demonstrates how international research partnerships can be harnessed for local economic impact.
- conducts world class research in continuous manufacturing and advanced crystallisation;
- conducts fundamental research;
- develops new solutions to company specific problems;
- delivers measurable successes that are of real benefit to society;
- creates commercial opportunities for start-ups and major global companies;
- produces a talent pipeline of highly skilled multi-disciplinary staff;
- influences policy, government, and regulators;
- understands and integrates with the broader supply chain context
- collaborates with world class business and academia on an international basis.
CMAC’s leading manufacturing research programme is funded by the EPSRC Manufacturing Research Hub programme. The University of Strathclyde is the hub with delivery achieved by a multidisciplinary and collaborative academic team at the UK universities of Bath, Cambridge, Imperial, Leeds, Loughborough and Sheffield. Research with impact, has grown through new projects supported by EPSRC, InnovateUK, EU and industry. CMAC is a founding member of International Institute of Advanced Pharmaceutical Manufacturing (I2APM,) with partners C-SOPS (US) and RCPE (Austria). As part of critical regulatory agenda CMAC and MIT organise a biennial conference with the FDA.
The £34M UK-RPIF scheme partnership established a world-class facility equipped with a comprehensive suite of continuous processing, process analysis, and characterisation equipment. The physical hub is within the new £89m Technology and Innovation Centre (TIC) at Strathclyde opened by HM the Queen in July 2015. This provides an open access approach across the academic and industrial community.
In 2016, TIC received an honourable mention in the International Society for Pharmaceutical Engineering (ISPE) Facility of the Year award, and the facility was shortlisted in 2018, for CPhI’s Excellence in Pharma Awards.
CMAC has a unique Doctoral Training Centre, which operates across the partner universities. CMAC also has joint doctoral training programmes in collaboration with NTU and as part of the NPL Scottish Hub. Training the next generation of scientists and engineers is vital to accelerating the adoption of continuous manufacturing. Additionally, a Master’s programme in Advanced Pharmaceutical Manufacturing is delivered at Strathclyde. A key deliverable is the CMAC talent pipeline of graduates moving into industry and academia.
CMAC benefits from strong industry engagement and leadership. An industry led membership organisation was created in 2011 and this has grown and developed over the years. The membership organisation operates under a pre-competitive, collaborative research and development model with senior level company support. The main industry partners (AstraZeneca, GSK, Novartis, Bayer, Lilly, Takeda, Roche and Pfizer) get an individual seat on the CMAC Board and an opportunity to influence the direction of future research and Hub activity. Integral to the CMAC ecosystem are the Tier 2 technology companies. These range from large companies, Siemens and PwC, to micro SMEs. This supportive environment helps translate research into equipment and products. In addition to CMAC members the Hub organises many open events for the broader industry landscape and collaborates with a wide range of additional companies locally, nationally and globally.
If you would like to reach out to discuss anything from the above case study, please get in touch.
Let us know if you would like to discuss contributing to the case studies we currently profile.